Table 1.
Relationship between CADM1/TSLC1 expression and clinicopathological variables of ESCC.
| Variable | CADM1/TSLC1 expression | p value | |
|---|---|---|---|
| Positive (n = 236) | Negative (n = 57) | ||
| Age (years) | 0.145 | ||
| <60 | 128 (54.2%) | 37 (64.9%) | |
| ≥60 | 108 (45.8%) | 20 (35.1%) | |
| Sex | 0.032 | ||
| Male | 171 (72.5%) | 33 (57.9%) | |
| Female | 65 (27.5%) | 24 (42.1%) | |
| Location | 0.674 | ||
| Upper thoracic | 25 (10.6%) | 4 (7.0%) | |
| Middle thoracic | 179 (75.8%) | 46 (80.7%) | |
| Lower thoracic | 32 (13.6%) | 7 (12.3%) | |
| Histological grade | 0.000 | ||
| I | 77 (32.6%) | 12 (21.1%) | |
| II | 145 (61.4%) | 18 (31.6%) | |
| III | 14 (6.0%) | 27 (47.3%) | |
| Depth of invasion | 0.791 | ||
| T1-2 | 46 (19.5%) | 12 (21.1%) | |
| T3-4 | 190 (80.5%) | 45 (78.9%) | |
| Tumor size (cm) | 0.410 | ||
| ≤5 | 165 (70.0%) | 43 (75.4%) | |
| >5 | 71 (30.0%) | 14 (24.6%) | |
| Lymph node metastasis | 0.997 | ||
| Positive | 116 (49.2%) | 28 (49.1%) | |
| Negative | 120 (50.8%) | 29 (50.9%) | |
| TNM stage | 0.905 | ||
| I-II | 118 (50.0%) | 28 (49.1%) | |
| III | 118 (50.0%) | 29 (50.9%) | |